binding affinity News and Research

RSS

Unique technology identifies drug candidates, speeds up drug development

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate.

From NanoTemper Technologies 24 Feb 2010

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Mutations within a conservative region of hepatitis C virus affect therapy

At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide.

30 Mar 2009

Veeco releases new BioScope Catalyst Life Science Atomic Force Microscope

Veeco Instruments Inc. announced today the release of its BioScope Catalyst Life Science Atomic Force Microscope (AFM).

2 Mar 2009

Biodegradable nanoprobe images new blood vessel growth

Angiogenesis, the growth of new blood vessels, plays a critical role in several chronic human diseases, including metastatic cancer. In fact, several new anticancer therapies are designed to starve tumors by shutting down angiogenesis, but the lack of a good assay for quantifying angiogenesis in the body has hampered the development of effective antiangiogenesis therapies.

18 Jan 2009

New folate antagonists selectively target pathway important in rheumatoid arthritis

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis.

13 Jan 2009

Wyeth and Santaris Pharma to collaborate on RNA-based medicines

Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

12 Jan 2009

Model unravels rules that govern how genes are switched on and off

For years, scientists have struggled to decipher the genetic instruction book that details where and when the 20,000 genes in a human cell will be turned on or off.

5 Dec 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

Cancer cell targeting using multiple aptamers conjugated on nanorods

Aptamers, short stretches of DNA or RNA that can act much like antibodies, have shown promise as targeting agents for selective nanoparticle trafficking to tumors.

16 Jan 2008

MIT model could improve some drugs' effectiveness

MIT researchers have developed a computer modeling approach that could improve a class of drugs based on antibodies, molecules key to the immune system.

24 Sep 2007

Scientists create sheets of protein-gold arrays

In groundbreaking research, scientists have demonstrated the ability to strategically attach gold nanoparticles -- particles on the order of billionths of a meter -- to proteins so as to form sheets of protein-gold arrays.

28 Jun 2007

Targeted tumor therapy has paramount consequences for future expansion of nuclear medicine

Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed.

20 Oct 2006

PET imaging of cerebral cannabinoid CB1 receptors with [11C]JHU75528

A team of Johns Hopkins researchers developed a new radiotracer - a radioactive substance that can be traced in the body - to visualize and quantify the brain's cannabinoid receptors by positron emission tomography (PET).

6 Jun 2006

Colorimetric screening detects DNA, small molecules and proteins

Using the unusual color properties of gold at the nanoscale, scientists at Northwestern University have developed a "litmus test" for DNA and small molecule binding that eventually could be used by pharmaceutical companies to rapidly identify promising candidates for new anti-cancer drugs.

11 Apr 2006

New targeted cancer drug delivery system

Prostate, breast and other cancer patients may be offered a new, stauncher targeted drug delivery system to treat their diseases in the next decade.

3 Nov 2005

Naturally occurring peptide hormones - candidates for the treatment of cancer, sexual dysfunction, eating disorders

Chemists at the University of Arizona have developed modified versions of naturally occurring peptide hormones that could be key to novel treatments of a variety of diseases, including eating disorders (anorexia, obesity), diabetes, sexual dysfunction and skin cancer.

1 Sep 2005

Scientist develops way to deliver promising genetic tool into living cells

By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.

6 Dec 2004